LYNPARZA tablets are indicated: in combination with abiraterone
and prednisone/prednisolone for the treatment of adult patients with
mCRPC in whom chemotherapy is not clinically indicated.²

ARPI=androgen receptor pathway inhibitor; mCRPC=metastatic castration-
resistant prostate cancer. 1. Clarke NW, et al. NEJM Evid.2022;1(9):doi:10.1056/
EVIDoa2200043; 2. LYNPARZA (olaparib). Summary of Product Characteristics.

For UK Healthcare Professionals only. This promotional asset has been fully
developed and funded by AstraZeneca and MSD. Click here for UK
prescribing information and adverse event reporting information.

ARPI=androgen receptor pathway inhibitor; mCRPC=metastatic castration-
resistant prostate cancer; PARPi=Poly(ADP-ribose) polymerase inhibitor.
1. Olaparib with abiraterone for untreated hormone relapsed metastatic
prostate cancer. NICE TA951. February 2024. https://www.nice.org.uk/
guidance/ta951. Accessed October 2025; 2. Scottish Medicines Consortium.
Olaparib (Lynparza) March 2024. Available at: https://
www.scottishmedicines.org.uk/medicines-advice/olaparib-lynparza-mcrpc-
full-smc2617/ Accessed October 2025.

For UK healthcare professionals only. This promotional asset has been fully
developed and funded by AstraZeneca and MSD. Click here for UK
prescribing information and adverse event reporting information.

ARPI=androgen receptor pathway inhibitor; HRRm=homologous
recombination repair mutation; mCRPC=metastatic castration-resistant
prostate cancer. 1. LYNPARZA (olaparib). Summary of Product Characteristics;
2. Clarke NW, et al. NEJM Evid.2022;1(9):doi:10.1056/EVIDoa2200043.

For UK healthcare professionals only. This promotional asset has been fully
developed and funded by AstraZeneca and MSD. Click here for UK
prescribing information and adverse event reporting information.